AI Engines For more Details: Perplexity Kagi Labs You
Lowering Blood Pressure: Lacidipine works by blocking calcium channels in blood vessels, leading to relaxation of smooth muscle cells in the vessel walls. This dilation of blood vessels reduces peripheral resistance, allowing blood to flow more easily, and ultimately lowers blood pressure. By controlling hypertension, lacidipine helps reduce the risk of complications such as stroke, heart attack, and kidney disease.
Angina Pectoris: Lacidipine may also be used in the treatment of angina pectoris, a condition characterized by chest pain or discomfort caused by reduced blood flow to the heart muscle. By dilating coronary arteries, lacidipine improves blood flow to the heart, relieving symptoms of angina and reducing the frequency and severity of episodes.
Vasospastic Angina: In addition to stable angina, lacidipine may be effective in the management of vasospastic angina (variant angina or Prinzmetal's angina). By relaxing coronary artery spasm, lacidipine can help alleviate chest pain associated with this condition and improve blood flow to the heart muscle.
Protection Against Cardiovascular Events: Beyond its blood pressure-lowering effects, lacidipine may have additional cardiovascular benefits. Some studies suggest that calcium channel blockers like lacidipine may reduce the risk of certain cardiovascular events, including stroke and myocardial infarction (heart attack), particularly in patients with hypertension and other risk factors.
Renal Protection: Lacidipine may offer renal protection by reducing blood pressure and improving renal blood flow. By lowering systemic blood pressure, lacidipine helps alleviate pressure on the kidneys, potentially slowing the progression of kidney disease in patients with hypertension or diabetic nephropathy.
Peripheral Arterial Disease: Lacidipine may be beneficial for individuals with peripheral arterial disease (PAD), a condition characterized by narrowed arteries in the legs, arms, stomach, or head. By improving blood flow to peripheral tissues, lacidipine can help alleviate symptoms such as leg pain, cramping, and numbness during physical activity.
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Bifidobacterium | Reduces |
| species | Bifidobacterium adolescentis | Reduces |
| species | Bifidobacterium longum | Reduces |
| species | Escherichia coli | Reduces |
| species | Lacticaseibacillus paracasei | Reduces |
| species | Parabacteroides distasonis | Reduces |
| subspecies | Bifidobacterium longum subsp. infantis | Reduces |
| subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.2 | 0.2 | |
| Acne | 0.5 | -0.5 | |
| ADHD | 4.2 | 0.5 | 7.4 |
| Age-Related Macular Degeneration and Glaucoma | 0.3 | 0.2 | 0.5 |
| Allergic Rhinitis (Hay Fever) | 1.6 | 2.5 | -0.56 |
| Allergies | 4.2 | 3.3 | 0.27 |
| Allergy to milk products | 1.4 | 0.8 | 0.75 |
| Alopecia (Hair Loss) | 1 | 1 | |
| Alzheimer's disease | 3 | 6.1 | -1.03 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 1.9 | 0.7 | 1.71 |
| Ankylosing spondylitis | 3.2 | 1.3 | 1.46 |
| Anorexia Nervosa | 0.2 | 2.5 | -11.5 |
| Antiphospholipid syndrome (APS) | 2.1 | 0.2 | 9.5 |
| Asthma | 1 | 0.6 | 0.67 |
| Atherosclerosis | 1.1 | 1.8 | -0.64 |
| Atrial fibrillation | 3.3 | 2 | 0.65 |
| Autism | 7.4 | 8.8 | -0.19 |
| Barrett esophagus cancer | 0 | 0.5 | 0 |
| benign prostatic hyperplasia | 0.1 | 0.1 | |
| Biofilm | 1.8 | 1.8 | |
| Bipolar Disorder | 1.2 | 1.4 | -0.17 |
| Brain Trauma | 0.6 | 0.6 | 0 |
| Cancer (General) | 3.7 | -3.7 | |
| Carcinoma | 2.8 | 2 | 0.4 |
| Celiac Disease | 1.2 | 3.1 | -1.58 |
| Cerebral Palsy | 1.5 | 1.5 | 0 |
| Chronic Fatigue Syndrome | 5 | 5.6 | -0.12 |
| Chronic Kidney Disease | 1.2 | 1.8 | -0.5 |
| Chronic Lyme | 0.6 | -0.6 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 2.5 | 0.8 | 2.13 |
| Chronic Urticaria (Hives) | 1.3 | 1.7 | -0.31 |
| Coagulation / Micro clot triggering bacteria | 1 | 1.8 | -0.8 |
| Colorectal Cancer | 3.9 | 1 | 2.9 |
| Constipation | 0.5 | 0.8 | -0.6 |
| Coronary artery disease | 1.6 | 1 | 0.6 |
| COVID-19 | 7.5 | 11.5 | -0.53 |
| Crohn's Disease | 5.3 | 4.6 | 0.15 |
| cystic fibrosis | 0.3 | 1 | -2.33 |
| deep vein thrombosis | 0.3 | 1.3 | -3.33 |
| Depression | 7.6 | 7.8 | -0.03 |
| Dermatomyositis | 0.5 | 0.5 | 0 |
| Eczema | 0.7 | 3.3 | -3.71 |
| Endometriosis | 2.7 | 0.5 | 4.4 |
| Eosinophilic Esophagitis | 0 | 0 | |
| Epilepsy | 2.7 | 1.4 | 0.93 |
| Fibromyalgia | 2.1 | 3 | -0.43 |
| Functional constipation / chronic idiopathic constipation | 5.5 | 3.8 | 0.45 |
| gallstone disease (gsd) | 1.8 | 0.8 | 1.25 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 1.1 | 1.4 | -0.27 |
| Generalized anxiety disorder | 1.4 | 2.7 | -0.93 |
| giant cell arteritis | 0.5 | -0.5 | |
| Glioblastoma | 0.5 | -0.5 | |
| Gout | 0.5 | -0.5 | |
| Graves' disease | 1 | 0.9 | 0.11 |
| Halitosis | 0.2 | 0.5 | -1.5 |
| Hashimoto's thyroiditis | 1.6 | 0.9 | 0.78 |
| Hidradenitis Suppurativa | 0.7 | 0 | 0 |
| High Histamine/low DAO | 2.1 | 1 | 1.1 |
| hypercholesterolemia (High Cholesterol) | 0.5 | 0.5 | |
| hyperglycemia | 0.1 | 1.4 | -13 |
| Hyperlipidemia (High Blood Fats) | 0.6 | 0.1 | 5 |
| hypersomnia | 0.6 | -0.6 | |
| hypertension (High Blood Pressure | 2.1 | 6.3 | -2 |
| Hypothyroidism | 1.5 | -1.5 | |
| Hypoxia | 0.4 | 0.4 | |
| IgA nephropathy (IgAN) | 3 | -3 | |
| Inflammatory Bowel Disease | 4.6 | 9.6 | -1.09 |
| Insomnia | 1.2 | 0.6 | 1 |
| Intelligence | 1 | 0.8 | 0.25 |
| Intracranial aneurysms | 1.4 | 0.1 | 13 |
| Irritable Bowel Syndrome | 2.8 | 1.7 | 0.65 |
| Liver Cirrhosis | 4 | 3.2 | 0.25 |
| Long COVID | 5.5 | 7.9 | -0.44 |
| Low bone mineral density | 0.8 | -0.8 | |
| Lung Cancer | 0.1 | 1 | -9 |
| Mast Cell Issues / mastitis | 0.6 | 1.5 | -1.5 |
| ME/CFS with IBS | 1.1 | 2.6 | -1.36 |
| ME/CFS without IBS | 1.6 | 1.1 | 0.45 |
| Menopause | 2.1 | 2.1 | |
| Metabolic Syndrome | 5.9 | 7.7 | -0.31 |
| Mood Disorders | 9.9 | 7.8 | 0.27 |
| multiple chemical sensitivity [MCS] | 1.5 | 0.5 | 2 |
| Multiple Sclerosis | 5.3 | 6.3 | -0.19 |
| Multiple system atrophy (MSA) | 1.4 | 1.5 | -0.07 |
| neuropathic pain | 0.9 | -0.9 | |
| Neuropathy (all types) | 1 | 0.1 | 9 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.2 | 0.2 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 2.5 | 6 | -1.4 |
| NonCeliac Gluten Sensitivity | 1.1 | 0.7 | 0.57 |
| Obesity | 5.4 | 3.8 | 0.42 |
| obsessive-compulsive disorder | 5.4 | 3.6 | 0.5 |
| Osteoarthritis | 2.5 | 0.5 | 4 |
| Osteoporosis | 1.3 | 0.7 | 0.86 |
| pancreatic cancer | 0.5 | 0.5 | |
| Parkinson's Disease | 6 | 7.1 | -0.18 |
| Polycystic ovary syndrome | 2.2 | 2.3 | -0.05 |
| Postural orthostatic tachycardia syndrome | 0.5 | 1 | -1 |
| Premenstrual dysphoric disorder | 1.1 | 0.2 | 4.5 |
| primary biliary cholangitis | 0.1 | -0.1 | |
| Psoriasis | 3.7 | 2.5 | 0.48 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 5.2 | 3 | 0.73 |
| Rosacea | 1.1 | 0.8 | 0.38 |
| Schizophrenia | 5.7 | 2.8 | 1.04 |
| scoliosis | 0.5 | 0.7 | -0.4 |
| Sjögren syndrome | 2.2 | 2.8 | -0.27 |
| Sleep Apnea | 1.9 | 1.5 | 0.27 |
| Slow gastric motility / Gastroparesis | 0.9 | 0.5 | 0.8 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.7 | 1 | -0.43 |
| Stress / posttraumatic stress disorder | 2 | 1.6 | 0.25 |
| Systemic Lupus Erythematosus | 3.6 | 1.8 | 1 |
| Tic Disorder | 0.7 | 1.4 | -1 |
| Tourette syndrome | 0.2 | -0.2 | |
| Type 1 Diabetes | 3.2 | 2.6 | 0.23 |
| Type 2 Diabetes | 5.7 | 5.7 | 0 |
| Ulcerative colitis | 2.7 | 3.7 | -0.37 |
| Unhealthy Ageing | 4.3 | 2.2 | 0.95 |
| Vitiligo | 2.3 | 2.2 | 0.05 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2024 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription
All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models.
Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [35.170.81 ]
Due to AI drones slamming this site, we have added IP blocking on excessive calls. Email us if you get blocked and send this [35.170.81 ]
